Role of consolidation therapy in transplant eligible multiple myeloma patients

Seminars in Oncology

Volumn 40, Issue 5, 2013, Pages 610-617

  Cavo, Michele ^a   Brioli, Annamaria ^a   Tacchetti, P ^a   Zannetti, B A ^a   Mancuso, K ^a   Zamagni, E ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

BORTEZOMIB; CISPLATIN; CYCLOPHOSPHAMIDE; CYTOTOXIC AGENT; DEXAMETHASONE; DOXORUBICIN; ETOPOSIDE; LENALIDOMIDE; MELPHALAN; THALIDOMIDE;

ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; BONE MARROW SUPPRESSION; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER PROGNOSIS; CANCER SURVIVAL; CHROMOSOME ABERRATION; CONSOLIDATION CHEMOTHERAPY; CONTINUOUS INFUSION; DEEP VEIN THROMBOSIS; DOSE RESPONSE; DRUG RESPONSE; EVENT FREE SURVIVAL; FATIGUE; GASTROINTESTINAL DISEASE; HERPES ZOSTER; HUMAN; IMMUNOMODULATION; INDUCTION CHEMOTHERAPY; INFECTIOUS COMPLICATION; LOW RISK POPULATION; MAINTENANCE THERAPY; METAPHASE; MINIMAL RESIDUAL DISEASE; MULTIPLE CYCLE TREATMENT; MULTIPLE MYELOMA; NEUROPATHIC PAIN; NEUTROPENIA; OVERALL SURVIVAL; PERIPHERAL NEUROPATHY; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PLASMA CELL; POST TREATMENT SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECURRENCE RISK; SURVIVAL TIME; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT OUTCOME;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BORONIC ACIDS; CLINICAL TRIALS AS TOPIC; CONSOLIDATION CHEMOTHERAPY; HUMANS; MULTIPLE MYELOMA; PYRAZINES; STEM CELL TRANSPLANTATION; THALIDOMIDE; TRANSPLANTATION, AUTOLOGOUS; TREATMENT OUTCOME;

EID: 84886934751     PISSN: 00937754     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.seminoncol.2013.07.001     Document Type: Article

References (32)

1. M. Attal, J.L. Harousseau, and A.M. Stoppa A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Francais du Myelome N Engl J Med 335 2 1996 91 97
2. J.A. Child, G.J. Morgan, and F.E. Davies High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma N Engl J Med 348 19 2003 1875 1883
3. J. Koreth, C.S. Cutler, and B. Djulbegovic High-dose therapy with single autologous transplantation versus chemotherapy for newly diagnosed multiple myeloma: a systematic review and meta-analysis of randomized controlled trials Biol Blood Marrow Transplant 13 2 2007 183 196
4. A. Kumar, M.A. Kharfan-Dabaja, A. Glasmacher, and B. Djulbegovic Tandem versus single autologous hematopoietic cell transplantation for the treatment of multiple myeloma: a systematic review and meta-analysis J Natl Cancer Inst 101 2 2009 100 106
5. M. Cavo, and M. Baccarani The changing landscape of myeloma therapy N Engl J Med 354 10 2006 1076 1078
6. M. Cavo, S.V. Rajkumar, and A. Palumbo International Myeloma Working Group consensus approach to the treatment of multiple myeloma patients who are candidates for autologous stem cell transplantation Blood 117 23 2011 6063 6073
7. M. Cavo, L. Pantani, and M.T. Petrucci Bortezomib-thalidomide- dexamethasone is superior to thalidomide-dexamethasone as consolidation therapy after autologous hematopoietic stem cell transplantation in patients with newly diagnosed multiple myeloma Blood 120 1 2012 9 19
8. H. Ludwig, B.G. Durie, and P. McCarthy IMWG consensus on maintenance therapy in multiple myeloma Blood 119 13 2012 3003 3015
9. M. Attal, J.L. Harousseau, and T. Facon Single versus double autologous stem-cell transplantation for multiple myeloma N Engl J Med 349 26 2003 2495 2502
10. M. Cavo, P. Tosi, and E. Zamagni Prospective, randomized study of single compared with double autologous stem-cell transplantation for multiple myeloma: Bologna 96 clinical study J Clin Oncol 25 17 2007 2434 2441
11. C.M. Segeren, P. Sonneveld, and B. van der Holt Overall and event-free survival are not improved by the use of myeloablative therapy following intensified chemotherapy in previously untreated patients with multiple myeloma: a prospective randomized phase 3 study Blood 101 6 2003 2144 2151
12. H. Goldschmidt Single vs double high-dose therapy in multiple myeloma: second analysis of the GMMG-HD2 trial Haematologica (10th International Myeloma Workshop Meeting Abstracts) 90 s1 2005 S38
13. J. Fermand High dose therapy supported with autologous stem cell transplantation in multiple myeloma: long term follow-up of the prospective studies of the MAG group Haematologica (10th International Myeloma Workshop Meeting Abstracts) 90 S1 2005 S40
14. M. Cavo, E. Zamagni, and P. Tosi Superiority of thalidomide and dexamethasone over vincristine-doxorubicindexamethasone (VAD) as primary therapy in preparation for autologous transplantation for multiple myeloma Blood 106 1 2005 35 39
15. S.V. Rajkumar, E. Blood, D. Vesole, R. Fonseca, and P.R. Greipp Phase III clinical trial of thalidomide plus dexamethasone compared with dexamethasone alone in newly diagnosed multiple myeloma: a clinical trial coordinated by the Eastern Cooperative Oncology Group J Clin Oncol 24 3 2006 431 436
16. J.L. Harousseau, M. Attal, and H. Avet-Loiseau Bortezomib plus dexamethasone is superior to vincristine plus doxorubicin plus dexamethasone as induction treatment prior to autologous stem-cell transplantation in newly diagnosed multiple myeloma: results of the IFM 2005-01 phase III trial J Clin Oncol 28 30 2010 4621 4629
17. H.M. Lokhorst, B. van der Holt, and S. Zweegman A randomized phase 3 study on theeffect of thalidomide combined with adriamycin, dexamethasone, and high-dose melphalan, followed by thalidomide maintenance in patients with multiple myeloma Blood 115 6 2010 1113-2
18. G.J. Morgan, F.E. Davies, and W.M. Gregory Cyclophosphamide, thalidomide, and dexamethasone as induction therapy for newly diagnosed multiple myeloma patients destined for autologous stem-cell transplantation: MRC Myeloma IX randomized trial results Haematologica 97 3 2012 442 450
19. M. Cavo, P. Tacchetti, and F. Patriarca Bortezomib with thalidomide plus dexamethasone compared with thalidomide plus dexamethasone as induction therapy before, and consolidation therapy after, double autologous stem-cell transplantation in newly diagnosed multiple myeloma: a randomised phase 3 study Lancet 376 9758 2010 2075 2085
20. P. Moreau, H. Avet-Loiseau, and T. Facon Bortezomib plus dexamethasone versus reduced-dose bortezomib, thalidomide plus dexamethasone as induction treatment prior to autologous stem cell transplantation in newly diagnosed multiple myeloma Blood 118 2011 5752 5758
21. L. Rosiñol, A. Oriol, and A.I. Teruel Superiority of bortezomib, thalidomide, and dexamethasone (VTD) as induction pretransplantation therapy in multiple myeloma: a randomized phase 3 PETHEMA/GEM study Blood 120 8 2012 1589 1596
22. P. Sonneveld, I.G. Schmidt-Wolf, and B. van der Holt Bortezomib induction and maintenance treatment in patients with newly diagnosed multiple myeloma: results of the randomized phase III HOVON-65/ GMMG-HD4 trial J Clin Oncol 20;30 24 2012 2946 2955
23. H. Ludwig, H. Avet-Loiseau, and J. Bladé European perspective on multiple myeloma treatment strategies: update following recent congresses Oncologist 17 5 2012 592 606
24. A. Chanan-Khan, and S. Giralt Importance of achieving a complete response in multiple myeloma, and the impact of novel agents J Clin Oncol 28 15 2010 2612 2624
25. B. Barlogie, E. Anaissie, and J. Haessler Complete remission sustained 3 years from treatment is a powerful surrogate for extended survival in multiple myeloma Cancer 113 2 2008 355 359
26. A.C. Rawstron, J.A. Child, and R.M. de Tute Minimal residual disease assessed by multiparameter flow cytometry in multiple myeloma: impact on outcome in the Medical Research Council Myeloma IX Study J Clin Oncol 31 20 2013 2540 2547
27. B. Barlogie, G. Tricot, and E. Rasmussen Total therapy 2 without thalidomide in comparison with total therapy 1: role of intensified induction and posttransplantation consolidation therapies Blood 107 7 2006 2633 2638
28. U.H. Mellqvist, P. Gimsing, and O. Hjertner Bortezomib consolidation after autologous stem cell transplantation in multiple myeloma: a Nordic Myeloma Study Group randomized phase III trial Blood 121 23 2013 4647 4654
29. X. Leleu, G. Fouquet, and B. Hebraud Consolidation with Vtd significantly improves the complete remission rate and time to progression following Vtd induction and single autologous stem cell transplantation in multiple myeloma Leukemia 2013 Apr 5 [Epub ahead of print]
30. M. Ladetto, G. Pagliano, and S. Ferrero Major tumor shrinking and persistent molecular remissions after consolidation with bortezomib, thalidomide, and dexamethasone in patients with autografted myeloma J Clin Oncol 28 12 2010 2077 2084
31. M. Attal, V. Cances-Lauwers, and G. Marit Lenalidomide maintenance after stem-cell transplantation for multiple myeloma N Engl J Med 366 2012 1782 1791
32. M. Roussel, N. Robillard, and P. Moreau Bortezomib, lenalidomide, and dexamethasone (VRD) consolidation and lenalidomide maintenance in frontline multiple myeloma patients: updated results of the IFM 2008 phase II VRD intensive program ASH Annual Meeting Abstracts 118 21 2011 1872